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Adaptive treatment planningPurpose: To develop and evaluate a fast, automated multi-criterial treatment planning approach for
adaptive high-dose-rate (HDR) intracavitary + interstitial brachytherapy (BT) for locally advanced cervi-
cal cancer.
Methods and materials: Twenty-two previously delivered single fraction MRI-based HDR treatment plans
(SFclin) were used to guide training of our in-house system for multi-criterial autoplanning, aiming for an
autoplan quality superior to the training plans, while respecting the clinically desired ‘‘pear-shaped” dose
distribution. Next, the configured algorithm was used to automatically generate treatment plans for 63
other fractions (SFauto). The SFauto plans were compared to the corresponding SFclin plans in blind pairwise
comparisons by an expert clinician. Then, the effect of adaptive autoplanning on total treatment (TT)
plans (external beam + 3 BT fractions) was evaluated for 16 patients by simulating the clinically applied
adaptive strategy to generate TTauto plans and compare them with the corresponding clinical treatments
(TTclin).
Results: In the blind comparisons, all SFauto plans were considered clinically acceptable. In 62/63 compar-
isons, SFauto plans were considered at least as good as, or better than the corresponding SFclin. The average
optimization time for autoplanning was 20.5 ± 19.2 s (range 4.4–106.4 s) per plan. In 14 of 16 TTauto plans,
the desired total dose of 90 Gy (EQD2) was obtained, compared to only 9 in the corresponding TTclin, while
autoplanning also decreased bladder and rectum doses.
Conclusions: Fast, fully-automated multi-criterial treatment planning for adaptive HDR-BT for locally
advanced cervical cancer is feasible. Autoplans were superior to corresponding clinical plans.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 148 (2020) 143–150 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Several systems for automated treatment planning for external
beam radiotherapy (EBRT) have been developed, demonstrating
consistent high plan quality, with automatically generated plans
often being preferred over manually generated plans [1–12].
In recent years, several approaches for high-dose-rate (HDR)
brachytherapy (BT) automated treatment planning (autoplanning)
have been proposed. For prostate cancer HDR-BT, Maree et al. and
Cui et al. [13,14] approximated the Pareto-front for plan selection,
allowing the user to make the final trade-off. A user-independent
approach was presented by Breedveld et al. [15], who developed
a system for automated multi-criterial treatment planning forprostate HDR-BT, based on their in-house, clinically applied auto-
planning system for EBRT, and demonstrated superiority of auto-
mated treatment planning over conventional HDR-BT treatment
planning.
A unique objective in locally advanced cervical cancer HDR-BT
planning is to not only achieve adequate target coverage and
acceptable organ-at-risk (OAR) doses, but to also realize this with
a pear-shaped dose distribution. For cervical cancer HDR-BT auto-
planning, Lessard et al. [16] proposed a dose-based objective func-
tion in which the weighted sum over the high-risk clinical target
volume (CTVHR), a manually contoured pear shape, and the OARs
was optimized. The relative weights of the structures needed to
be tuned per patient in order to achieve clinically favorable treat-
ment plans. Hanania et al. [17] used tuned settings for the inverse
planning algorithm from the TPS, but also required fine-tuning per
patient. Guthier et al. [18] focused on target coverage maximiza-
tion (weighted sum of CTVHR and intermediate risk CTV) under
dose-volume based constraints on the OARs. They did not explicitly
Table 1
Overview of the clinical planning aims. Presented EQD2 are for total treatments (TT),








CTVHR D90% 85 Gy >90 < 95 Gy
Bladder D2cc 90 Gy <80 Gy
Rectum D2cc 75 Gy <65 Gy
Sigmoid D2cc 75 Gy <70 Gy
Small
Bowel
D2cc 75 Gy <60 Gy
Other objectives
Pear-shaped isodose lines around intracavitary applicator
Minimal dosimetric contribution from needles relative to intracavitary
applicator, preferably below 20%
Smooth dose distribution: no steep dose gradients and no hot or cold spots
within the intracavitary applicator
After delivering >93.8 Gy to the CTVHR, prioritize OAR sparing over increasing
CTVHR dose
Prioritize small bowel sparing towards goal over sparing other OARs
144 Automated treatment planning for cervical cancer HDR-BTaddress other aims such as generating a pear-shaped dose distribu-
tion, and minimizing OAR dose. A way to avoid manual tuning for
cervical cancer HDR-BT is presented by Shen et al. [19], who used
deep reinforcement learning to mimic actions of a manual planner
by predicting suitable weight adjustments. The optimization prob-
lem consisted of constraints on the CTVHR and an artificial pear-
shape, while the dose to the OARs was minimized by using a
weighted-sum function. There was no explicit steering on trade-
offs between the dose in the target and OARs and there were no
constraints on the dose to the OARs.
In this study, we follow the work by Breedveld et al. [15] to
develop an approach for fully automated treatment planning for
cervical cancer HDR-BT. Hereto, the autoplanning system was
adapted for combined intracavitary + interstitial (IC + IS) HDR-BT
for locally advanced cervical cancer. Two studies for autoplanning
validation were conducted: (1) blind clinician comparisons of sin-
gle fraction autoplans (SFauto) with their corresponding clinical
plans (SFclin), and (2) comparisons of cumulative, total treatment
(TT; EBRT + 3 BT fractions) dose distributions generated with adap-
tive autoplanning of the three BT fractions (TTauto), with corre-
sponding clinically delivered adaptive plans (TTclin).Methods and materials
Patients
The patients in this study were treated between 2015 and 2018
for stage 2.B-4.A cervical cancer. Treatment consisted of EBRT (23
fractions of 2 Gy or 25–27 fractions of 1.8 Gy) and BT (three or four
fractions spread over three weeks). Patients were treated using the
Utrecht applicator (Elekta AB, Stockholm, Sweden) with up to 10
interstitial needles. In each BT fraction, after applicator implanta-
tion an MRI or CT was obtained for adaptive planning.
For this study, only MRI-based fractions were considered
because they were fully contoured (CTVHR + OARs), resulting in a
database with MRIs and corresponding clinical dose distributions
of 85 fractions belonging to 34 patients. The average CTVHR volume
was 29.4 ± 12.5 cm3 (range 8.5–92.0 cm3). In 56 fractions intersti-
tial needles were implanted (average 4.4 ± 2.4 needles). A subset of
48 fractions belonged to 16 patients with an MRI in all three BT
sessions available for this study. The remaining 37 plans belonged
to 18 patients for whom one or more fractions were not selected
because they were CT-based, or problems occurred when retriev-
ing the data.Clinical planning
State-of-the-art clinical treatment planning [20] was performed
manually in our clinical treatment planning system Oncentra-
Brachy (version 4.5.1, Elekta AB, Stockholm, Sweden), using delin-
eated scans with a reconstructed applicator, while considering
already delivered EBRT and BT dose.
An overview of the clinical planning aims as used between 2015
and 2018 at our institution is provided in Table 1. Limits and goals
for the dosimetric parameters are defined for total treatments (TT:
EBRT + BT) and presented as equivalent doses of 2 Gy per fraction
(EQD2). The dose received during EBRT was assumed to be uniform.
No deformable registration was applied before summing EBRT and
BT dosimetric plan parameters [21].
The general goal at the start of BT treatment planning was to
evenly distribute remaining OAR tolerance doses and the required
additional CTVHR dose amongst three or four fractions. However, in
the first fractions higher OAR doses could be accepted if it was
expected to be necessary to obtain the minimum CTVHR dose of
85 Gy in the total treatment. The maximum OAR tolerances in
the total treatments were however always respected.Clinical BT planning started from a standard normalized treat-
ment plan, in which the dwell positions in the intracavitary part
of the applicator were evenly active. Dwell positions in the needles
were then activated and dwell times in the standard plan were
adjusted graphically by dragging isodose lines in the TPS. This pro-
cess took 15–30 min per plan.Automated planning
Erasmus-iCycle was used as a basis for automated plan genera-
tion [10,11,15]. The system uses a so-called ‘wish-list’ to steer the
multi-criterial optimization. The wish-list contains hard planning
constraints and prioritized objectives, and defines the lexico-
graphic plan generation. A well-tuned wish-list results in clinically
acceptable treatment plans with favorable trade-offs between the
treatment objectives. The treatment site specific wish-lists are con-
structed in an iterative tuning process in close collaboration with
the expert clinicians, using repetitive autoplanning, plan evalua-
tion and wish-list adjustments for a small set of training patients
(Electronic appendix of [11]).
Wish-list
The wish-list used for autoplanning in this study (Table 2) was
configured with an expert clinician (Dr. Jan-WillemMens, JWM), in
line with clinical planning. Twenty-two of the 85 available treat-
ment fraction MRIs with corresponding clinical dose distributions
were used for training. Training fractions were selected to cover
the full range of CTVHR volumes. Because of the adaptive planning,
the wish-list contains fraction-specific dosimetric parameters. All
activated dwell positions (IC + IS) were available during automatic
optimizations.
In line with the clinical protocol (Table 1), the final wish-list
contained hard constraints for the D2cc of the OARs (bladder, rec-
tum, sigmoid and small bowel). The DVH-based cost-functions in
the wish-list were implemented similar to the approach presented
in [15]. To constrain the dwell time modulation and enforce
smooth dose distributions, a quadratic cost-function which penal-
izes the second derivative of the dwell times of adjacent dwell
positions in the intracavitary applicator, was used as constraint,
similar to fluence map smoothing in EBRT [22]. The dose in the
CTVHR was optimized in three steps (priorities 1, 5 and 7 in Table 2).
A pear-shaped dose distribution was created by optimizing on two
artificially created structures (‘pear’ and ‘pear-inside’) which fol-
low the dwell positions in the tandem and ovoids of the applicator
Table 2
Wish-list for per-fraction autoplanning for HDR-BT for cervical cancer, and total cumulative treatment aims for EBRT + 3BT (last column). Per-fraction parameters (Lij dose limit for
structure i in fraction j, and Gi;pj dose goal for structure i in priority p and fraction j) in the wish-list were patient-specific and related to the performed adaptive planning
(Section ‘‘Clinical planning”).N equals the number of needles. All doses are presented in EQD2. The arrows indicate whether the objective wasminimized (down) ormaximized (up).
Constraints per fraction
Structure i Constraint function Dose limit in fraction j,Lij Cumulative dose limit




Bladder (B) D2cc LBj Gy 90 Gy
Rectum (R) D2cc LRj Gy 75 Gy
Sigmoid (S) D2cc LSj Gy 75 Gy
Small Bowel (SB) D2cc LSBj Gy 75 Gy
Intracavitary dwell
positions
Quadratic function Dwell time modulation <24* s/mm2
Objectives per fraction
Priority p Structure i Objective in fraction j Goal for fraction j Cumulative dose goal





1 CTVHR (T) " VGT;1
j
Gy 90% D90% > 90 Gy
2 Pear " V5.9* Gy 96%
3 Pear Inside " Quadratic underdose (penalize D < 8* Gy) 0.1* Gy2
4 Needles ; sneedles(Eq (1)) 0.1 + 0.015 N*, sufficient if ½(0.1 + 0.015 N)*
5 CTVHR " VGT;5
j
Gy 90% D90% > 93.8 Gy
6 Bladder ; VGB;6
j
Gy 2 cc D2cc < 80 Gy
6 Rectum ; VGR;6
j
Gy 2 cc D2cc < 65 Gy
6 Sigmoid ; VGS;6
j
Gy 2 cc D2cc < 70 Gy
6, weight 4* Small Bowel ; VGSB;6
j
Gy 2 cc D2cc > 65 Gy
7 CTVHR " VGT;7
j
Gy 90% D90% > 95 Gy
* Parameters indicated with an asterisk were chosen empirically based on training plans and were tweaked in collaboration with the expert clinician.
Fig. 1. Automatically generated dose distribution (left) and clinical dose distribution (right) with projected applicator for a single fraction for an example patient in the
applicator coordinate system. The top slices (plane perpendicular to the intra uterine tube) demonstrate improved CTVHR coverage for a reference dose of 9.8 Gy in the
automatically generated dose distribution. The white arrows indicate positions of improved coverage. The bottom slices (plane parallel to the intra uterine tube) show the
pear-shaped dose distribution. The shown isodose lines represent the physical doses.
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areas with the target or OARs (priorities 2 and 3). The 4th priority
in the wish-list aims at reducing the relative dose contribution
from the needles using sneedles as defined by:
sneedles ¼ tneedlesttotal ð1Þ
where ttotal represents the total accumulated dwell time for all dwell
positions (IC + IS) and tneedles the total dwell time for only the inter-
stitial part of the implant. The goal value was related to the number
of available needles N (Table 2). The priority 6 objective aims at
reducing OAR dose, where dose reduction in the small bowel was
considered more relevant than other OARs and was thus assigned
a relative weighting factor of 4.
Blind comparisons of single fraction autoplans (SFauto) and clinical
plans (SFclin)
To enable fair comparisons between SFauto and SFclin plans, the
fraction-specific parameters Lij and G
i;p
j in Table 2 were based on
the constraints and goals used for the corresponding SFclin. In this
way, plans based on the same treatment goals could be compared,
the only difference being the way of plan generation, manually or
automated.
Comparison of total treatment adaptive autoplans (TTauto) with
clinical plans (TTclin)
For the TT comparisons, an automated adaptive strategy was
simulated, in line with clinical practice (Section ‘‘Clinical plan-
ning”). To compute Lij and G
i;p
j , the total dose received up to thisFig. 2. Histograms showing results of the 63 clinician’s blind comparisons of a single frac
clinician’s visual analog scale scores (Appendix A).fraction (EBRT and 0, 1 or 2 automatically generated BT fractions)
was taken into account, while aiming at an equal spread of
required or allowed dose to the CTVHR and OARs over the remain-
ing fractions. However, if the absolute minimum cumulative dose
goal of 85 Gy (EQD2) to the CTVHR seemed to be infeasible, up to
5% more dose than Lij was allowed to the OARs in the first fraction
and up to 3% in the second fraction. In the third and final fraction,
the maximum tolerances (Table 1) were always respected.
Optimization details
The dose optimization points (voxels) were sampled with a
density of 300 voxels/cc for all structures. To speed up computa-
tions, only the parts of the OARs within a 35 mm radius from the
dwell positions were taken into account during optimizations.
Beyond this distance, the maximum expected dose is anyway
much less than the constrained values, which was verified by
visual inspection for the training patients and had no impact on
the resulting plan. Both the dose-volume cost-functions and the
relative needle contribution cost-function (Eq. (1)) are non-
convex. We used our in-house developed interior-point solver with
extended functionality for non-convex optimization for these func-
tions, see [23,15]. The optimizations were performed on an Intel
Core i7-7700 with 4 cores running at 3.6 GHz. After optimization
in Erasmus-iCycle, the dwell-times were imported in the clinical
TPS for final dose calculation and comparisons with clinical plans.Validation of automated planning
First, blind comparisons of single fraction autoplans (SFauto)
with corresponding clinical plans (SFclin) were performed for thetion autoplan with the corresponding clinically delivered plan. The x-axis shows the
M. Oud et al. / Radiotherapy and Oncology 148 (2020) 143–150 14763 SFclin plans that were not used in wish-list tuning. The pairwise
plan comparisons were performed in the clinical TPS by an expert
clinician (JWM), using the 3D dose distributions and DVH parame-
ters of these plans, while considering also DVH parameters of pre-
vious BT fractions and the EBRT course, that were also provided.
There were no pre-defined criteria for the comparisons; the clini-
cian followed his routine workflow for plan evaluation. The clini-
cian first assessed the clinical acceptability of both plans,
followed by assessments of differences in (i) overall quality, (ii)
CTVHR dose and (iii) OAR dose, using a visual analog scale (Appen-
dix A).
Second, total treatment adaptive autoplans (TTauto) were com-
pared with the clinical plans (TTclin) for the 16 patients with an
MRI in each BT fraction. Pairwise differences in the dosimetric plan
parameters listed in Table 1 were assessed in the clinical TPS. After
importing the dwell-times of the autoplans in the clinical TPS, the
DVH parameters did not exactly match the Erasmus-iCycle opti-
mized ones due to small differences in the implementation of vol-
ume and dose-point definition between the two systems.
Therefore, D90% CTVHR in the last TTauto fraction could be rescaled
up to 93.8 Gy if possible within OAR limits, or down to 95 Gy in
case the D90% of TTauto exceeded 95 Gy. Statistical significance of
differences in plan parameters was assessed with the paired Wil-
coxon signed-rank test.Fig. 3. Scatter plots showing CTVHR D90%, and bladder, rectum, sigmoid and small
bowel D2cc for the automatically generated and clinical total treatment plans (TTauto
and TTclin). Each patient has her own colored symbol. Improvements in CTVHR D90%
for TTauto plans, and bladder and rectum D2cc were statistically significant. There
were no significant differences for the sigmoid and small bowel.Results
Fig. 1 shows an example of an SFauto plan, compared to the cor-
responding SFclin plan, clearly showing the desired pear-shape in
both dose distributions. All 63 SFauto plans were considered clini-
cally acceptable by the clinician, while 1 clinical plan was (in ret-
rospect) not. The clinician’s scores, presented in Fig. 2,
demonstrate superiority for the automatically generated plans in
terms of overall plan quality. In 60/63 cases SFauto was preferred
over SFclin, in 2/63 cases the quality of the plans was considered
equal (score = 0) and for 1/63 cases SFclin was preferred over SFauto
because of a more favorable small bowel dose. The scoring for
CTVHR shows a similar trend with in 62/63 cases SFauto similar or
better than the clinical plan. For the OARs, the differences were less
pronounced. Still, in 29/63 cases SFauto was considered better, in
21/63 cases both plans were similar and for 13/63 cases SFclin
was preferred.
The average optimization time for the 63 SFauto plans was 20.
5 ± 19.2 s (range 4.4–106.4 s).
For the total treatment adaptive autoplans, the last fraction
could be rescaled for 10/16 patients due to differences in TPSes
to improve CTVHR dose, with an average absolute difference in
D90% of 0.26 ± 0.21 Gy (range 0.10–0.80 Gy). Total treatment dosi-
metric parameters are compared in Fig. 3. The required minimum
CTVHR D90% of 85 Gy (Table 1) was always obtained for TTauto,
whereas for two TTclin plans it was not. Consequently, these two
clinically delivered treatments did not strictly adhere to the
requirements for clinical acceptability. This was due to an unfavor-
able anatomy of these patients, making manual treatment plan-
ning challenging. The first goal for the CTVHR was to achieve a
minimum dose of 90 Gy. This was obtained in 14/16 TTauto plans,
compared to 9/16 TTclin plans. For all 16 patients the CTVHR D90%
was highest in the TTauto plan. This improvement was statistically
significant (p = 0.0004) and clinically relevant with a mean D90% for
the TTauto plans of 93.0 ± 2.0 Gy compared to 89.4 ± 3.2 Gy for TTclin,
with differences ranging from +1.4 to +6.0 Gy.
For the D2cc of the OARs for the total treatment adaptive plans,
the prescribed limits (Table 1) were never exceeded, neither for
TTauto, nor for TTclin (Fig. 3). The dose in the bladder was signifi-
cantly reduced in the TTauto plans compared to TTclin (p = 0.05) witha mean reduction of 0.87 Gy (range 1.8 to 6.6 Gy). The rectum
was also significantly more spared (p = 0.04), with a mean reduc-
tion in D2cc of 1.4 Gy (range 4.9 to 6.3 Gy). There were no signif-
icant differences in D2cc of the sigmoid (p = 0.3) and small bowel
(p = 0.3).Discussion
Optimization of the dose distribution for locally advanced cervi-
cal cancer HDR-BT is a complex problem, due to the special
requirements of the dose distribution (pear-shaped), delivery
restrictions (contributions by needles) and the adaptive treatment
schedule. To the best of our knowledge, we have presented the first
automated multi-criterial treatment planning solution considering
each of the complexities, and capable of generating clinically favor-
able dose distributions. In the blind comparisons, all 63 single frac-
tion autoplans were considered clinically acceptable by the expert
clinician, and 62 of the 63 autoplans were scored similar or better
than the clinically delivered plans.
In this study, we also proposed an adaptive treatment approach
with a quantitative recipe for setting all fraction-specific treatment
goals, depending on previously delivered doses. This adaptive
148 Automated treatment planning for cervical cancer HDR-BTautoplanning approach was in line with the (somewhat less rigidly
defined) clinical adaptive planning. Adaptive autoplanning was
compared with clinical planning based on cumulative total treat-
ment doses, as there exists no clinical scenario for comparisons
of single fraction doses in adaptive treatment. Nonetheless, all sin-
gle fraction autoplans fulfilled the clinical requirements (Table 1).
The proposed procedure with adaptive single fraction autoplan-
ning resulted in overall higher quality of total treatment dose dis-
tributions compared to clinical total dose. For all 16 patients, the
CTVHR D90% was highest with automated planning. The number of
patients who reached the desired minimum CTVHR dose increased
from 9/16 in the clinical treatment to 14/16 when using automated
treatment planning.
With an average optimization time of 20.5 s per fraction, this
approach shortens treatment planning times considerably, which
are currently between 15 and 30 min in clinical practice.
The wish-list in this study was tailored to the treatment plan-
ning procedure at the Erasmus MC at the time of the treatment
of the patients. The Erasmus MC has recently made the transition
to the Embrace II protocol1. As most challenging requirements in
this protocol are similar to those for the current HDR-BT cervix
plans, it is expected that the current wish-list can be adapted to gen-
erate clinically preferable dose distributions for Embrace II as well.
In addition to limits and goals for the D90% of the HR-CTV and D2cc
of the OARs, the EMBRACE II protocol includes more goals, for exam-
ple for the D98% of the CTVHR, intermediate-risk CTV and gross tumor
volume. Because the Embrace II protocol contains more objectives
compared to the protocol in this study, manual treatment planning
becomes even more challenging and an automatic approach could
become even more valuable. However, tuning the desired trade-
offs between the different objectives will be more time-consuming.
In the future, our HDR-BT autoplanning approach could be
extended with optimization of the interstitial needle configuration
(positions and insertion depth) of the applicator, by simulating the
10 possible needle positions and including an objective to mini-1 https://www.embracestudy.dkmize the number of used needles and their insertion depths in
the wish-list. Needles could then be implanted based on an indi-
vidualized and automatically generated treatment plan that is
optimized both for the dwell times and number and position of
needles.
In conclusion, this study demonstrated that fast, fully-
automated multi-criterial treatment planning for locally advanced
cervical cancer HDR-BT was feasible, based on a well-tuned, clini-
cally relevant wish-list. Blind pairwise clinician comparisons of
single fraction manual- and autoplans pointed at a strong prefer-
ence for the autoplans. Cumulative total doses resulting from adap-
tive treatment were also favorable when generated with per-
fraction autoplanning. With autoplanning, planning times reduced
from the current 15–30 min to 20.5 s on average.Disclosure
The Erasmus MC Cancer Institute has research collaborations
with Elekta AB, Stockholm, Sweden, and Accuray Inc, Sunnyvale,
USA. The Delft University of Technology—Radiation Science &
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